Acetogenic Bacteria Patents: Who Leads, Where the Gaps Are 2026
Acetogenic Bacteria Pathway Balancing Patents: Who's Filing and What's Still Open
Concentrated at the top. The five most active filers together hold 70.2% of all 104 records in scope, and the top ten hold 91.3% — this is a field with a small set of repeat filers, not a broad crowd. Filings rose from 2 in 2017 to a peak of 24 in 2022, then eased — the tracked 2021-to-2024 window shows 4 down to 3, a 25% decline. Treat the final one to two years as incomplete rather than as evidence the field is winding down.
- 1GENOMATICA INC25
- 2LANZATECH NZ INC15
- 3LANZATECH INC14
- 4MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV11
- 5DANMARKS TEKNISKE UNIV8
See the full acetogenic bacteria pathway balancing analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in acetogenic bacteria pathway balancing?
The assignee ranking covers 29 companies and institutions across 104 records in scope. The leading assignee holds 25 records, well ahead of the fifth-ranked filer at 8 and the tenth at 3 — a steep drop-off that shows this is a concentrated field rather than a broad one. The top five filers combined hold 70.2% of all records, and the top ten hold 91.3%, so most of the remaining 19 ranked assignees each contribute only one or a few filings.
Is patent filing in this field growing or slowing down?
Filing activity rose from 2 records in 2017 to a peak of 24 in 2022, then declined to 3 by 2024 — a 25% drop over that tracked three-year window. However, publication typically lags actual filing by roughly 18 months, so 2025 and 2026 figures in any dataset are still incomplete at the point of measurement. It is more accurate to say activity has cooled from its 2022 peak than to call the field currently in decline.
What patent classes cover acetogenic bacteria pathway engineering?
Almost all records fall under C12N (microorganisms and genetic engineering, 99.0% of the 104 records) and C12P (fermentation and enzymatic synthesis, 95.2%). Smaller but notable shares appear in C07K (peptides and proteins, 15.4%) and C12R (microorganism indexing, 10.6%), with sugars/nucleic acids, enzyme/DNA-based measurement, bioinformatics and wastewater treatment each under 3%. Because a single record can carry multiple IPC classes, these percentages add up to more than 100%.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Acetogenic Bacteria Pathway Balancing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.